-
UPCOMING EVENTS
2021.06.08
We are pleased to announce the acceptance of our abstract, “RNA-seq Analysis of Liver from Diabetic and NASH Model Mouse Treated with Streptozotocin, High-Fat Diet”, for presentation in the category “Integrated Physiology—Liver” at the 81st Annual Meeting of the American Diabetes Association, to be held from June 25 to 29, 2021.
-
UPCOMING EVENTS
Visit SMC Laboratories at BIO Digital 2021
2021.05.26
We are joining the world’s largest virtual biotech partnering and education event, convening thousands of global biotech leaders and innovators.
-
NEWS RELEASE
New Partnership with cancer model search service Repositive, Inc.
2021.05.21
SMC Laboratories, Inc. is pleased to announce a partnership with Repositive, Inc., a UK-based bespoke cancer model search service.
-
NEWS RELEASE
2021.05.12
Amplia Therapeutics, which is our client, has announced the results of pharmacology study using a STAM™ mouse model.
-
NEWS RELEASE
Chemomab announces enrollment of first patient in phase 2a study of CM-101 in NASH
2021.05.04
Chemomab Ltd.(Israel) announced on 26 April, 2021, enrollment of first patient in phase 2a study of CM-101 in NASH.
-
PRODUCTS AND SERVICES
Pre-clinical studies for cirrhosis: Carbon tetrachloride (CCl4)-induced liver fibrosis
2021.04.26
The CCl4-induced liver fibrosis model is a model that forms bridging fibrosis around the portal vein region.
-
NEWS RELEASE
Wnt/β-catenin in our NASH-HCC model: How does it correlate to human liver cancer?
2021.04.09
The main cause of hepatocellular carcinogenesis today is chronic liver disease following HCV and HBV infection.
-
NEWS RELEASE
2021.04.02
CohBar, Inc. (USA) announced on March 29, 2021, that the completion of enrolment in the Phase 1b stage of the CB4211 clinical study of NASH and obesity.
-
NEWS RELEASE
2021.02.22
Gannex (Shanghai, China) has announced positive clinical results in overweigth and obse subjects for its THR-b agonist ASC41.
-
NEWS RELEASE
2021.02.15
TERNS Pharmaceuticals, Inc. (USA) has announced FDA clearance of investigational new drug aplication for first-in-human phase 1 trial of TERN-501, its THR-beta agonist in development for the treatment of NASH.
-
NEWS RELEASE
Inventiva announces design of Phase III clinical trial with Ianifibranor in NASH
2021.02.04
Inventiva (France) has announced design of Phase III clinical trial with Ianifibranor in NASH
-
NEWS RELEASE
2021.01.22
Hepion pharma (NJ), which is our client, has announced positive top line data for low dose CRV431 in Phase 2a "AMBITION" clincal trial for treatment of advanced NASH.
